Neurotechnology is advancing rapidly, from medical implants to consumer brain-computer interfaces, bringing immense promise but also unprecedented risks. Neural data is uniquely sensitive, revealing thought and emotion, making security and governance essential. A holistic, layered security and governance framework is necessary to protect trust, safeguard identity and unlock the transformative potential of neurotechnology.

Less than two years after becoming the first person to receive Neuralink’s brain-computer interface, Noland Arbaugh is living a completely transformed life. Paralyzed from the shoulders down following a 2016 swimming accident, Arbaugh underwent a two-hour robotic surgery that implanted Neuralink’s Telepathy device into his motor cortex. This has allowed him to control devices and even play video games using only his mind.

High-bandwidth brain–computer interfaces rely on invasive surgical procedures or brain-penetrating electrodes. Here we describe a cortical 1,024-channel thin-film microelectrode array and we demonstrate its minimally invasive surgical delivery that avoids craniotomy in porcine models and cadavers. We show recording and stimulation from the same electrodes to large portions of the cortical surface, and the reversibility of delivering the implants to multiple functional regions of the brain without damaging the cortical surface.

The brain-computer interface developer Precision Neuroscience has put forward a study detailing the experiences of its first human patients—showing its minimally invasive approach is capable of both collecting high-bandwidth neural data and delivering stimulation without penetrating deep into tissue. 

A new clinical study could make it possible to control Apple’s Vision Pro headset using just brain signals, without the need for risky surgery. The project, led by Santa Barbara–based startup Cognixion, combines non-invasive brain-computer interface (BCI) technology with Apple Vision Pro’s built-in accessibility features, aiming to help people with serious speech and mobility challenges communicate more naturally.

China is aggressively advancing brain-computer interface (BCI) technology through substantial investments and policies, targeting breakthroughs by 2027 in healthcare, manufacturing, and consumer sectors. Key innovations include semi-invasive implants and standards for medical devices, positioning China as a global leader despite ethical challenges and competition. This push aims to dominate neural innovation by 2030.

The challenge of brain health calls for radical collaboration. It is only when we cross the road, yell over the back fence, and venture down the laneway that we begin to find ways to truly invest in and scaffold every brain. When the stars align – conversations, grants, clinical partners, industry partners – possibility turns into impact. Collaboration at its best builds collective power by leveraging our individual strengths.

Neuralink has a backlog of 10,000 individuals interested in having its N1 device drilled into their skulls, according to President and Co-Founder Dongjin (DJ) Seo. The company has implanted the N1 into 12 clinical trial patients so far; Seo expects the number to grow to 25 by year's end.People can sign up to participate in the company's clinical trials online, but to qualify, they must have either limited or no ability to use their hands due to a cervical spinal cord injury or ALS.

Find out why Synchron Stentrode is on TIME's list of 2025's best inventions.

For years, people with paralysis have used brain-computer interfaces to turn neural signals into actions by thinking about the actions they would like to take: typing words, controlling robotic arms, producing speech. But new research shows that the interfaces could translate not only intended speech, but internal thoughts as well. Sort of.

In January 2024, Musk founded Neuralink to complete the world's first clinical trial of invasive brain-computer interface device implantation, which caused a sensation all over the world. Unlike the invasive brain-computer interface technology that requires the implantation of electrodes in the open skull, the interventional brain-computer interface avoids craniotomy by placing electrodes from the blood vessels, thus reducing the risk of surgery. This method is well combined with clinical medicine. The solid foundation of neurosurgical intervention technology makes the interventional brain-computer connection The mouth has the advantages of small trauma, high signal acquisition accuracy, short recovery period and so on.

The vein of Trolard shows promise as a target for endovascular BCIs given its consistent presence and favorable dimensions. Nonetheless, constrictions and steep angulation at the SSS confluence pose challenges for device deployment. A new framework is necessary for the classification of cortical venous anatomy, to guide patient selection and procedural planning, which will require further development and validation.

Micro-CT and the histomorphometric techniques we developed are comparable and can both be used to identify incorporation of a Stentrode implanted in cerebral vessels.

Long story short, neural interfaces implanted throughout the body have demonstrated great success in treating a growing variety of conditions. Despite these successes, the longevity of implanted neural interface systems are impeded by mechanical, technological, and biological barriers. Mechanical and electronic failures can occur in any of the components of the implanted system. The immune response to an implanted neural interface consists of acute and chronic phases and differs between the central and peripheral nervous systems. Advances in material science and engineering are actively working to reduce the tissue response to implanted neural interfaces by reducing their size and stiffness as well as by using factors to reduce inflammation.

High-fidelity intracranial electrode arrays for recording and stimulating brain activity have facilitated major advances in the treatment of neurological conditions over the past decade. Traditional arrays require direct implantation into the brain via open craniotomy, which can lead to inflammatory tissue responses, necessitating development of minimally invasive approaches that avoid brain trauma. Here we demonstrate the feasibility of chronically recording brain activity from within a vein using a passive stent-electrode recording array (stentrode).

The impact of placing electrodes within a blood vessel and adjacent to the blood vessel wall was most obvious when looking at the phase responses at frequencies below 10 kHz. Conclusion: Our results show that intravascular electrodes, like those in subdural and epidural positions, show electrical properties that are suitable for recording. These results provide support for the use of intravascular arrays in clinically relevant neural prostheses and diagnostic devices. Significance: Comparison of electrochemical impedance of the epidural, intravascular, and subdural electrode array showed that all three locations are possible placement options, since impedances are in comparable ranges.

This work demonstrated that EIS could be used to determine the viability of electrode implanted chronically within a blood vessel. Impedance measurements alone were not observed to be a useful predictor of alterations occurring at the electrode tissue interface. However, measurement of 100 Hz phase angles was in good agreement with the capacitive changes predicted by the ECM and consistent with suggestions that this represents protein absorption on the electrode surface. 100 Hz phase angles stabilized after 8 days, consistent with histologically assessed samples.

In conclusion, our 3D brain slice injury model was successful as a tool for testing a biomaterial implantation therapy, highlighting the use of complex organotypic models for biomaterial testing, to close the gap between simple in vitro 2D models and complex in vivo models. The slices require technically simple procedures and limited training, and are highly cost-effective and humane versus live animal models. Accordingly, they offer the capacity to become a standardised screening model to evaluate neuromaterials, prior to therapeutic testing in live animal models.

A Harvard startup is developing a softer device to monitor head injuries — one that doesn’t damage surrounding tissue.

Tadalafil, which has the longest half-life among PDE-5 inhibitors, does not prevent endothelial apoptosis as much as nimodipine, but it still prevents smooth muscle cell proliferation in the tunica media, restores damaged endothelial integrity, increases cerebral blood flow, and is thought to have various neuroprotective functions through the PI3K/AKT/eNOS signaling pathway. We believe that more in-depth research on tadalafil in the future will prove the therapeutic potential of this drug for DCI.